RBC Capital analyst Ben Hendrix raised the firm’s price target on HCA Healthcare to $329 from $322 and keeps an Outperform rating on the shares. The market balked at the company’s Q1 earnings beat that fell short of buy-side expectations, but RBC remains “encouraged” by the overall demand backdrop for HCA Healthcare, the analyst tells investors in a research note. The firm further cites indications of solid commercial uptake at the tail end of re-determinations, which gives RBC confidence in rate momentum continuing for HCA through year-end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare Announces Q1 Results and Shareholder Dividend
- HCA Healthcare backs FY24 EPS view $19.70-$21.20, consensus $20.64
- HCA Healthcare reports Q1 adjusted EPS $5.36, consensus $5.01
- Options Volatility and Implied Earnings Moves Today, April 26, 2024
- Notable companies reporting before tomorrow’s open
